INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW
Rabeprazole sodium is a proton pump inhibitor with actions and uses similar to omeprazole. It is given orally as enteric-coated rabeprazole tablets and normally taken in the morning. For the treatment of severe ulcerative gastrooesophageal reflux desease, the usual dose is 20 mg once daily for 4 to 8 weeks.
In the USA, a further 8-week course is permitted for the healing of erosive 
Target of the Work
The aim of the present study is to develop a simple ultra performance liquid chromatography (UPLC) method for the determination of rabeprazole sodium in tablets and compare the results of HPLC. UPLC is an emerging liquid chromatography technique which enables significant reduction in run time and solvent consumption. To the best of our knowledge, no UPLC method has been reported yet for the determination of rabeprazole in pharmaceutical formulations.
EXPERIMENTAL

Materials and Reagents
Standard rabeprazole sodium was received as a gift from Metro Labs Ltd (Baddi, India). Rabeprazole sodium tablets were purchased from a local pharmacy (Pepraz®, 10 mg, East West Pharma, India). HPLC grade acetonitrile was purchased from Merck (Mumbai, India). High purity water was obtained using Millipore Milli-Q water purification system (Billerica, MA, USA). All other reagents were of analytical grade.
Instrumentation
The HPLC system was a Waters 2695 binary pump plus auto sampler and a 2996 photo diode array as well as 2487 UV detector (Waters Corporation, Milford, USA) was used for all method development and validation.
The UPLC analysis was performed on a Waters Acquity UPLC system (Waters Corporation, Milford, USA) equipped with a binary solvent manager, an auto sampler, and a column manager consisting of a column oven and a TUV detector.
For dissolution studies, Labindia 2000 dissolution apparatus (A sixtablet dissolution unit [Labindia, Mumbai, India]) was used.
Preparation of Standard
A stock solution of 1.0 mg/mL was prepared by dissolving an appropriate amount of rabeprazole sodium in 10 mM potassium hydroxide solution. A working solution of 10 µg/mL was prepared from this stock solution by serial dilution.
Preparation of Test Solution from Tablets
Twenty tablets were weighed and powdered. Powder equivalent to 50 mg of rabeprazole sodium was transferred to a 100 mL volumetric flask and extracted with 10 mM potassium hydroxide solution for 10 min. The solution was diluted suitably to 10 µg/mL and filtered through a 0.45 µm Millipore nylon filter paper.
Dissolution Sample Preparation
The dissolution test followed the procedure stipulated by the United States Pharmacopoeia USP (711) using apparatus 2 with paddles. The paddle speed was 100 rpm and reaming dissolution conditions were followed as per US FDA recommendations. During dissolution, the temperature of the media was maintained at 37 ± 0.5°C. For delayed-release rabeprazole sodium tablets, the US FDA recommends a dissolution test in 700 mL of 0.1 N HCl for 2 hours (Samples were collected for the estimation of rabeprazole sodium), after which 300 mL of 0.6 M Tris-HCl buffer (pH 8.0) was added to the medium and the dissolution test was continued for 45 min (Samples were collected for the estimation of rabeprazole sodium). Auto sampling was used to collect 10 mL samples at intervals over the test period. The samples were immediately filtered through a 0.45 µm Millipore nylon filter. The first 2 mL sample was discarded prior to collection of the samples for analysis.
RESULTS AND DISCUSSION
Optimization of Chromatographic Method
The main aim of the developed method was to achieve separation and quantification of rabeprazole using an isocratic mobile phase with a UPLC system. The UPLC method was developed to reduce the run time of the method and solvent consumption for routine analysis such as assay, dissolution and content uniformity during quality assurance. Detection of rabeprazole was adequate at 280 nm. The initial trial was conducted using HPLC and chromatographic separation was obtained on a Waters symmetry C 18 column (150 x 4.6 mm, 5 micron). Rabeprazole is an acid-labile compound and to avoid any degradation, a mobile phase with basic pH was selected. The mobile phase was optimized in the ratio of 10 mM potassium dihydrogen phosphate buffer (pH 7.4, adjusted with potassium hydroxide solution) to acetonitrile of 65:35 (v/v) with a flow rate of 1.0 mL/min and injection volume 20 µL.
While developing the UPLC method, basic chromatographic conditions of the HPLC method, in terms of column, solvents and UV detection, were followed. In selecting the UPLC column, its stability at the higher pH was taken into consideration to preserve the column's long life. For rabeprazole sodium, the recommended FDA media for dissolution solution studies is pH 8.0. The optimized mobile phase pH used in the present study is also on the basic side.
Most commercial C 18 columns are not stable at high pH on the longer run, which results in shortening their life span. Waters Acquity BEH C 18 (50 mm x 2.1 mm, 1.7 micron) column was found to be more suitable and stable at a pH of 8.0. The peak was sharp and acceptable and the injection volume was reduced from 20 to 5 µL. The flow rate also scaled down from 1.0 to 0.4 mL/min. 
Method Validation
The developed HPLC method was validated according to ICH and FDA guidelines in terms of precision, ruggedness, linearity, specificity, selectivity, robustness, LOD, LOQ and accuracy.
System Suitability
Standard solution was used for system suitability check. System suitability was analysed in terms of USP tailing factor (≤ 2.0), USP theoretical plates count (≥ 30000) and % RSD for five replicate injections (should be ≤ 2.0). The system suitability results for the proposed UPLC method are given in Table 4 .3. The results prove with respect to USP tailing factor, USP theoretical plates and % RSD that the optimized UPLC method fulfils these requirements within the accepted limits.
Precision
The precision of the method was evaluated by carrying out six independent assays of test samples against a qualified reference standard and the % RSD of assay was calculated. The intermediate precision of the method was also evaluated using different analysts, columns (Different lot of Waters Acquity BEH C 18 [50 x 2.1 mm, 1.7 micron]) and instruments (Different UPLC system of Waters Acquity) in the same laboratory. The result is shown in Table 4 .5. 
Robustness
To determine the robustness of the developed method, experimental conditions were deliberately altered and system suitability parameters were checked. The flow rate of the mobile phase was 0.4 mL/min. To study the effect of flow rate, it was changed by 0.05 units from 0.35 mL/min to 0.45 mL/min. The proportion of acetonitrile in the mobile phase (35 %) was changed by ± 3.5 % and the UV detection wavelength (280 nm) was changed by ± 3 nm. To study the effect of pH variation in the mobile phase, pH was altered by ± 0.2 units, i.e., 7.2 and 7.6. Changes in chromatographic parameters, i.e., theoretical plates, tailing factor and % RSD were evaluated for the method. In all the deliberately varied chromatographic conditions, the assay results were between 98 % and 101 %, and no significant changes were obtained in chromatographic parameters. This shows the robustness of the developed method.
The results are shown in Table 4 .6. 
Application of the Developed Method
When the developed method was used to analyse a commercial brand of the rabeprazole sodium tablet formulation, the mean recovery of six replicates was 99.69 % with a % RSD of 0.52. The percent recovery value indicates noninterference from the excipients present in the dosage form.
Application of the developed method to withdrawn rabeprazole sodium tablet dissolution samples, mean release in acid (pH 1.2) media was 2.8 % (for an average of 6 tablets) with % RSD of 4.5 and alkaline (pH 8.0 buffer) media was 97.2 % (for an average of 6 tablets) with % RSD of 3.2. Both the assay and dissolution test analyses were performed within 45 min, indicating the analysis' rapidity using UPLC method.
Conclusion
The new, isocratic RP-UPLC method proved to be simple, linear, precise, accurate, robust, rugged and rapid. The developed method is capable of giving faster elution and maintaining good separation more than what was achieved with conventional HPLC. The short retention time of 1.49 min allows the analysis of a large number of samples in a short period of time and so is more cost-effective for routine analysis in the pharmaceutical industries. The developed method was successfully applied to the rabeprazole sodium tablet's dissolution study. It is suitable for the rapid and accurate quality control of rabeprazole sodium in tablet formulations.
